Cytokinetics (NASDAQ:CYTK) Issues Quarterly Earnings Results, Beats Estimates By $0.13 EPS

Key Points

• Cytokinetics beat quarterly expectations, reporting an adjusted loss of $1.50 per share versus the expected $1.63 loss, while revenue of $28.62 million exceeded estimates of $17.59 million. However, revenue fell 57.1% year over year and the net loss widened from the prior-year quarter.
• MYQORZO launch momentum was strong, generating $25.3 million in second-quarter product revenue with 1,500 patients dispensed and more than 700 U.S. prescribers. The company also reported positive Phase III results for aficamten in non-obstructive hypertrophic cardiomyopathy and plans a supplemental NDA filing in the fourth quarter of 2026.
• Financial risks remain despite substantial liquidity. Cytokinetics ended the quarter with roughly $1.7 billion in cash and investments, but raised full-year R&D and SG&A expense guidance to $860 million–$890 million; shares fell 5.7% after the results, even as analysts maintained generally bullish ratings and price targets.

Cytokinetics (NASDAQ:CYTK - Get Free Report) announced its earnings results on Thursday. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, topping the consensus estimate of ($1.63) by $0.13, FiscalAI reports. The business had revenue of $28.62 million for the quarter, compared to analysts' expectations of $17.59 million. During the same quarter last year, the firm earned ($1.12) earnings per share. The firm's quarterly revenue was down 57.1% compared to the same quarter last year.

Here are the key takeaways from Cytokinetics' conference call:

• MYQORZO launch momentum exceeded expectations, with $25.3 million in Q2 net product revenue, 1,500 patients dispensed, more than 700 U.S. prescribers, and greater than 40% exit share of new-to-brand prescriptions. Medicare coverage reached nearly 90% parity, while commercial coverage exceeded 50%.
• Aficamten’s ACACIA-HCM Phase III trial met both primary endpoints in non-obstructive HCM, improving KCCQ scores and peak VO2 without new safety signals. The company plans to submit a supplemental NDA for the nHCM indication in Q4 2026, potentially expanding MYQORZO to a substantially larger patient population.
• International expansion progressed with the German launch, U.K. marketing authorization and NICE reimbursement guidance, and reimbursement approval in the Netherlands. The company expects a U.K. launch later this year, followed by additional European launches through 2027.
• Cytokinetics ended Q2 with approximately $1.7 billion in cash and investments after raising $760 million, providing funding for commercialization and pipeline development. However, the net loss widened to $198.8 million, and full-year combined R&D and SG&A expense guidance was increased to $860 million–$890 million.
• The broader specialty-cardiology pipeline continued advancing, with COMET-HF enrolling more than one-third of patients, AMBER-HFpEF expected to complete its first cohort in the second half of 2026, and the adolescent cohort of CEDAR-HCM enrolling ahead of schedule.

Cytokinetics Trading Down 5.7%

Shares of CYTK stock traded down $4.61 during trading hours on Friday, hitting $76.76. The company's stock had a trading volume of 3,604,418 shares, compared to its average volume of 1,732,641. The stock has a market cap of $9.55 billion, a PE ratio of -10.63 and a beta of 0.38. Cytokinetics has a 12-month low of $32.89 and a 12-month high of $88.31. The company has a 50 day moving average of $78.91 and a 200 day moving average of $70.90.

Cytokinetics News Summary

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Myqorzo uptake is encouraging. Management and analysts highlighted strong early traction for Myqorzo, supporting the view that the drug could become an important commercial growth driver. CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong
• Positive Sentiment: Quarterly results exceeded expectations. Cytokinetics reported revenue of $28.6 million versus consensus estimates near $17.6 million and a loss of $1.50 per share, narrower than the expected $1.63 loss. Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analysts raised their targets. Needham increased its target from $102 to $112 and maintained a “buy” rating, while Citizens JMP raised its target from $105 to $110 and kept a “market outperform” rating. These actions indicate analysts see meaningful upside if the launch continues to perform. Analyst Price Target Updates
• Neutral Sentiment: The commercial launch is still early. RBC viewed the earnings beat as supportive of Myqorzo’s launch, but investors will likely focus on prescription growth, reimbursement and the pace at which sales offset launch expenses.
• Negative Sentiment: Profitability and cash flow remain major concerns. Revenue fell 57.1% year over year, while Cytokinetics posted a $179.2 million operating loss and used $159.8 million in operating cash during the quarter. Higher launch costs and the absence of milestone payments also weighed on results, despite the $1.17 billion cash balance. Cytokinetics Q2 2026 Earnings: Revenue Beats but Losses Persist
• Negative Sentiment: Reported losses widened from the prior-year quarter. The quarterly loss increased from $1.12 per share a year earlier to $1.50, underscoring that CYTK remains dependent on successful commercialization and future financing or milestone opportunities. Cytokinetics Reports Q2 Loss, Beats Revenue Estimates

Analysts Set New Price Targets

A number of brokerages have recently weighed in on CYTK. Truist Financial set a $106.00 price target on Cytokinetics in a research note on Tuesday, May 5th. Morgan Stanley boosted their target price on shares of Cytokinetics from $90.00 to $103.00 and gave the stock an "overweight" rating in a research report on Wednesday, May 6th. Citigroup restated a "market outperform" rating on shares of Cytokinetics in a research note on Friday. JPMorgan Chase & Co. lifted their price objective on shares of Cytokinetics from $92.00 to $97.00 and gave the stock an "overweight" rating in a research note on Tuesday, May 12th. Finally, Stifel Nicolaus boosted their price objective on shares of Cytokinetics from $98.00 to $108.00 and gave the company a "buy" rating in a report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Cytokinetics currently has a consensus rating of "Moderate Buy" and an average target price of $100.85.

Insider Buying and Selling

In other Cytokinetics news, CEO Robert I. Blum sold 7,500 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $84.92, for a total transaction of $636,900.00. Following the sale, the chief executive officer directly owned 377,830 shares of the company's stock, valued at approximately $32,085,323.60. This trade represents a 1.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director B Lynne Parshall sold 5,000 shares of the business's stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $74.08, for a total value of $370,400.00. Following the completion of the transaction, the director directly owned 15,784 shares of the company's stock, valued at $1,169,278.72. The trade was a 24.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 115,179 shares of company stock valued at $9,126,054 over the last 90 days. Insiders own 2.60% of the company's stock.

Institutional Investors Weigh In On Cytokinetics

Several hedge funds have recently modified their holdings of the company. Pacer Advisors Inc. grew its holdings in Cytokinetics by 76.5% in the fourth quarter. Pacer Advisors Inc. now owns 27,783 shares of the biopharmaceutical company's stock valued at $1,765,000 after purchasing an additional 12,043 shares during the period. Invesco Ltd. lifted its holdings in Cytokinetics by 30.3% in the 4th quarter. Invesco Ltd. now owns 204,878 shares of the biopharmaceutical company's stock valued at $13,018,000 after purchasing an additional 47,629 shares in the last quarter. Corient Private Wealth LLC lifted its stake in shares of Cytokinetics by 527.1% in the fourth quarter. Corient Private Wealth LLC now owns 30,184 shares of the biopharmaceutical company's stock worth $1,918,000 after buying an additional 25,371 shares in the last quarter. Creek Drive Management Group LLC acquired a new position in shares of Cytokinetics during the 4th quarter worth approximately $635,000. Finally, Vident Advisory LLC boosted its stake in Cytokinetics by 1.4% during the fourth quarter. Vident Advisory LLC now owns 16,455 shares of the biopharmaceutical company's stock worth $1,046,000 after buying an additional 234 shares during the last quarter.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company's most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source